Changes in prostate cancer aggressiveness over a 12-year period in Korea

Korean Journal of Urology

Volumn 53, Issue 10, 2012, Pages 680-685

  Kim, Doejung ^a   Choi, Daeheon ^a   Lim, Ju Hyun ^a   Yoon, Jong Hyun ^b   Jeong, In Gab ^a   You, Dalsan ^a   Hong, Jun Hyuk ^a   Ahn, Hanjong ^a   Kim, Choung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b National Medical Center   (South Korea)

Author keywords

Korea; Neoplasm grading; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; DISEASE SEVERITY; GLEASON SCORE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY; TUMOR DIFFERENTIATION;

EID: 84868573243     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2012.53.10.680     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 2011;43:1-11.
3. Chi BH, Chang IH. Prostate cancer: recent trends in Korea. Urol Int 2010;85:88-93.
4. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009;24:995-1003.
5. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate 2006;66:1285-91.
6. Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007;14:78-85.
7. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170(6 Pt 2):S21-5.
8. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
9. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999;17:3167-72.
10. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. Eur Urol 2000;38:74-8.
11. Whittemore AS. Prostate cancer. Cancer Surv 1994;19-20:309-22.
12. Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, et al. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology 2006;68:820-4.
13. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002;87:13-5.
14. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
15. Murphy GP, Busch C, Abrahamsson PA, Epstein JI, McNeal JE, Miller GJ, et al. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994;162:7-42.
16. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 2012;44:11-24.
17. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
18. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166: 416-9.
19. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002;60: 458-63.
20. Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 2006;67:343-8.
21. Smith EB, Frierson HF Jr, Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer 2002;94:2282-7.
22. Xu DD, Sun SD, Wang F, Sun L, Stackhouse D, Polascik T, et al. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology 2009;74:654-8.
23. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167(2 Pt 1):528-34.
24. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-5.
25. Egawa S, Suyama K, Arai Y, Tsukayama C, Matsumoto K, Kuwao S, et al. Treatment outcome by risk group after radical prostatectomy in Japanese men. Int J Urol 2001;8:295-300.
26. Hsu YS, Wang JS, Wu TT. E-cadherin expression in prostate adenocarcinomas in Chinese and its pathological correlates. Urol Int 2004;73:36-40.
27. van Houten ME, Gooren LJ. Differences in reproductive endocrinology between Asian men and Caucasian men: a literature review. Asian J Androl 2000;2:13-20.
28. Wu AH, Whittemore AS, Kolonel LN, Stanczyk FZ, John EM, Gallagher RP, et al. Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men. Cancer Epidemiol Biomarkers Prev 2001;10:533-8.
29. Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179-82.
30. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670-5.